THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Clinical trials for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) explained in plain language.
Never miss a new study
Get alerted when new THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) trials appear
Sign up with your email to follow new studies for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Last-Chance drug access for serious illnesses
Disease control AVAILABLEThis program provides access to the drug ruxolitinib for patients with serious conditions like certain blood cancers and severe graft-versus-host disease. It is for people who have no other treatment options and cannot join a standard clinical trial. The program allows doctors to…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC